{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:31Z","timestamp":1790887771598,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN275201800001I"],"award-info":[{"award-number":["HHSN275201800001I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017973","name":"International Maternal Pediatric Adolescent AIDS Clinical Trials Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchromb.2025.124470","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T12:46:59Z","timestamp":1737204419000},"page":"124470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development and validation of an LC-MS\/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots"],"prefix":"10.1016","volume":"1252","author":[{"given":"Gerard Aime","family":"Kenfack Teponnou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Spaltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthinus van der","family":"Merwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Zangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-8699","authenticated-orcid":false,"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124470_b0005","unstructured":"World Health Organization, Key updates to the treatment of drug-resistant tuberculosis: Rapid communication. https:\/\/iris.who.int\/bitstream\/handle\/10665\/378472\/B09123-eng.pdf?sequence=1 2024 (accessed 24 October 2024)."},{"key":"10.1016\/j.jchromb.2025.124470_b0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01925-2021","article-title":"Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China","volume":"59","author":"Zheng","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jchromb.2025.124470_b0015","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.jchromb.2025.124470_b0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2025.124470_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.1063453","article-title":"Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies","volume":"13","author":"Alffenaar","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jchromb.2025.124470_b0030","first-page":"2500","article-title":"Review: available analytical methods for the estimation of first line, second line oral and newer anti-TB drugs","volume":"12","author":"Jani","year":"2021","journal-title":"Int. J. Pharm. Sci. Res."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124470_b0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10408347.2019.1605876","article-title":"A critical review of HPLC-based analytical methods for quantification of Linezolid","volume":"50","author":"Fernandes","year":"2019","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jchromb.2025.124470_b0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinms.2018.10.002","article-title":"Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs","volume":"14","author":"Kuhlina","year":"2019","journal-title":"Clin. Mass Spectrom."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170663","article-title":"Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania","volume":"12","author":"Ebers","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jchromb.2025.124470_b0050","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/10408347.2018.1451298","article-title":"Critical review on the analytical methods for the estimation of clofazimine in bulk, biological fluids and pharmaceutical formulations","volume":"48","author":"Patil","year":"2018","journal-title":"Crit. Rev. Anal. Chem."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124470_b0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4269\/ajtmh.17-0889","article-title":"Dried blood spots for global health diagnostics and surveillance: opportunities and challenges","volume":"99","author":"Lim","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124470_b0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1373\/clinchem.2017.275966","article-title":"Review: State of the Science in Dried Blood Spots","volume":"64","author":"Freeman","year":"2018","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124470_b0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/13993003.00599-2016","article-title":"Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV","volume":"48","author":"Zuur","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124470_b0070","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/infdis\/jis270","article-title":"Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs","volume":"205","author":"Alffenaar","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124470_b0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic Drug Monitoring by dried blood spot: Progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"27","key":"10.1016\/j.jchromb.2025.124470_b0080","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.2174\/138161211797470174","article-title":"Dried Blood Spots: A new tool for tuberculosis treatment optimization","volume":"17","author":"Vu","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jchromb.2025.124470_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","article-title":"Clinical feasibility of dried blood spots: Analytics, validation, and applications","volume":"130","author":"Enderle","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2025.124470_b0090","year":"2018","journal-title":"Bioanalytical Method Validation: Guidance for Industry"},{"key":"10.1016\/j.jchromb.2025.124470_b0095","year":"2022","journal-title":"Scientific Guidelines"},{"issue":"13","key":"10.1016\/j.jchromb.2025.124470_b0100","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124470_b0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug. Monit."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124470_b0110","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/jac\/dkv447","article-title":"Drug\u2013drug interactions between bedaquiline and the antiretrovirals lopinavir\/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB","volume":"71","author":"Pandie","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124470_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124470_b0120","doi-asserted-by":"crossref","first-page":"e01521","DOI":"10.1128\/AAC.01521-17","article-title":"Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis","volume":"62","author":"Denti","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0125","doi-asserted-by":"crossref","first-page":"e00794","DOI":"10.1128\/aac.00794-23","article-title":"Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis","volume":"68","author":"Ali","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2025.124470_b0130","unstructured":"CTV, Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care. https:\/\/ctv.veeva.com\/study\/building-evidence-for-advancing-new-treatment-for-rifampicin-resistant-tuberculosis-rr-tb-comparin 2024 (Accessed 04 March 2024)."},{"issue":"5","key":"10.1016\/j.jchromb.2025.124470_b0135","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/clinchem\/44.5.1024","article-title":"Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies","volume":"44","author":"Linnet","year":"1998","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124470_b0140","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/clinchem\/25.3.432","article-title":"Incorrect least-squares regression coefficients in method-comparison analysis","volume":"25","author":"Cornbleet","year":"1979","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajo.2008.09.032","article-title":"Correlation, Agreement, and Bland-Altman Analysis: Statistical Analysis of Method Comparison Studies","volume":"148","author":"Bunce","year":"2009","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124470_b0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tjem.2018.09.001","article-title":"Bland-Altman analysis: A paradigm to understand correlation and agreement","volume":"18","author":"Do\u011fan","year":"2018","journal-title":"Turk. J. Emerg. Med."},{"key":"10.1016\/j.jchromb.2025.124470_b0155","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/bmj.310.6975.298","article-title":"Statistics notes: The normal distribution","volume":"310","author":"Altman","year":"1995","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124470_b0165","doi-asserted-by":"crossref","first-page":"e4068","DOI":"10.1002\/bmc.4068","article-title":"Quantitative analysis of clofazimine (Lamprene\u00ae), an antileprosy agent, in human dried blood spots using liquid chromatography\u2013tandem mass spectrometry","volume":"32","author":"Li","year":"2017","journal-title":"Biomed. Chromatogr."},{"issue":"21","key":"10.1016\/j.jchromb.2025.124470_b0170","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.1021\/acs.analchem.8b03512","article-title":"Evaluation of the Capitainer-B Microfluidic Device as a New Hematocrit-Independent Alternative for Dried Blood Spot Collection","volume":"90","author":"Velghe","year":"2018","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124470_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.35995\/tmj20200210","article-title":"Analysis of the Variability of the Pharmacokinetics of the Long Half-Life Drug Amiodarone in Bioequivalence Studies","volume":"2020","author":"Shleghm","year":"2021","journal-title":"Timisoara Med."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00401706.1969.10490657","article-title":"American Society for Quality: Procedures for Detecting Outlying Observations in Samples","volume":"11","author":"Grubbs","year":"1969","journal-title":"Technometrics"},{"issue":"11","key":"10.1016\/j.jchromb.2025.124470_b0185","doi-asserted-by":"crossref","first-page":"e02399","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis","volume":"65","author":"Ngwalero","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124470_b0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2013.78","article-title":"Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver","volume":"94","author":"Chu","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.jchromb.2025.124470_b0200","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/dta.2195","article-title":"Development of a dried blood spot HPLC-PDA method for the analysis of linezolid and ciprofloxacin in hospital-acquired pneumonia patients","volume":"9","author":"Ferrone","year":"2017","journal-title":"Drug. Test. Anal."},{"key":"10.1016\/j.jchromb.2025.124470_b0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpba.2012.04.007","article-title":"Rapid and sensitive LC-MS\/MS method for the analysis of antibiotic linezolid on dried blood spot","volume":"67\u201368","author":"la Marca","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.jchromb.2025.124470_b0210","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3343\/alm.2016.36.5.489","article-title":"Multiplex Assay of Second-Line Anti-Tuberculosis Drugs in Dried Blood Spots Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry","volume":"36","author":"Lee","year":"2016","journal-title":"Ann. Lab. Med."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124470_b0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/IJAM.IJAM_54_17","article-title":"Bland\u2013Altman plot: A brief overview","volume":"3","author":"Kaur","year":"2017","journal-title":"Int. J. Acad. Med."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124470_b0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Lessons in biostatistics: Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem. Med. (zagreb)"},{"issue":"11","key":"10.1016\/j.jchromb.2025.124470_b0225","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.01054-12","article-title":"Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"56","author":"Vu","year":"2012","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T01:44:50Z","timestamp":1740620690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":45,"alternative-id":["S1570023225000224"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124470","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC-MS\/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124470"}}